The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support
Abstract
Precision medicine trials and targeted therapies have shifted to the forefront of oncology. Although targeted therapies have shown initial promise, implementation across the broad landscape of oncology has many challenges. These limitations include an incomplete understanding of the functional significance of variant alleles as well as the need for clinical research and practice models that are more patient-centered and account for the complexity of individual patient tumors. Furthermore, successful implementation of targeted therapies will also be predicated on efforts to standardize the framework for patient management support. Here, we review current implementations of targeted therapies in precision oncology and discuss how “actionability” is defined for molecular targets in cancer therapeutics. We also comment on the growing need for bioinformatics tools and data platforms to complement advances in precision oncology. Finally, we discuss current frameworks for integrating precision oncology into patient management and propose an integrated model that combines features of molecular tumor boards and decision support systems. Mol Cancer Ther; 16(12); 2645–55. ©2017 AACR. See related article by Pilié et al., p. 2641
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In parallel, the use of somatic cancer testing has increased as therapies targeted to specific mutational events have entered clinical practice (these developments are reviewed elsewhere131,132).”
From A brief history of human disease genetics (2020) · cites this paper as [132]
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Hauschild, A., Grob, J., Демидов, Л. В., Jouary, T., Gutzmer, R., Millward, M. J., Rutkowski, P. L., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 3,050
SIFT web server: predicting effects of amino acid substitutions on proteins
Sim, N.-L., Kumar, P. N., Hu, J., Henikoff, S., Schneider, G., & Ng, P. C. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks539 · Cited by 2,419
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Predicting the functional impact of protein mutations: application to cancer genomics
Reva, B. A., Antipin, Y., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr407 · Cited by 2,046
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M. D., Tavtigian, S. V., Nathanson, K. L., Devilee, P., Meindl, A., Couch, F. J., Southey, M. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1501341 · Cited by 947
Capriotti, E., Calabrese, R., & Casadio, R. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl423 · Cited by 940
Automated inference of molecular mechanisms of disease from amino acid substitutions
Li, B., Krishnan, V. G., Mort, M. E., Xin, F., Kamati, K. K., Cooper, D. N., Mooney, S. D., & Predrag Radivojac, A. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp528 · Cited by 818
González-Pérez, A., & López-Bigas, N. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.03.004 · Cited by 772
PANTHER version 10: expanded protein families and functions, and analysis tools
Mi, H., Poudel, S., Muruganujan, A., Casagrande, J. T., & Thomas, P. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1194 · Cited by 770
Functional annotations improve the predictive score of human disease-related mutations in proteins
Calabrese, R., Capriotti, E., Fariselli, P., Martelli, P. L., & Casadio, R. (2009) · Human Mutation · doi:10.1002/humu.21047 · Cited by 685
Hoff, D. D. V., Stephenson, J. J., Rosen, P. J., Loesch, D. M., Borad, M. J., Anthony, S. P., Jameson, G., Brown, S., Cantafio, N. A., Richards, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5983 · Cited by 650
Inherited Susceptibility to Common Cancers
Foulkes, W. D. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802968 · Cited by 583
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A. M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 538
Self-citationAllen, E. M. V., Wagle, N., Stojanov, P., Perrin, D., Cibulskis, K., Marlow, S., Jané‐Valbuena, J., Friedrich, D. C., Kryukov, G. V., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 533
Carter, H. K., Chen, S., Işık, L., Tyekucheva, S., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., & Karchin, R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1133 · Cited by 448
Patient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 286
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Wheler, J. J., Jankú, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D. D., Falchook, G. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3043 · Cited by 241
Self-citationA Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Meric‐Bernstam, F., Johnson, A. M., Holla, V. R., Bailey, A. M., Brusco, L., Chen, K., Routbort, M. J., Patel, K. P., Zeng, J., Kopetz, S., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv098 · Cited by 202
Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience
Schwaederle, M. C., Parker, B. A., Schwab, R. B., Fanta, P. T., Boles, S. G., Daniels, G. A., Bazhenova, L. A., Subramanian, R., Coutinho, A., Ojeda‐Fournier, H., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0405 · Cited by 196
Self-citationCancer Genomics: Technology, Discovery, and Translation
Tran, B., Dancey, J. E., Kamel‐Reid, S., McPherson, J. D., Bedard, P. L., Brown, A. M. K., Zhang, T., Shaw, P. H., Onetto-Pothier, N., Stein, L. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2316 · Cited by 188
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Schwaederle, M. C., Parker, B. A., Schwab, R. B., Daniels, G. A., Piccioni, D. E., Kesari, S., Helsten, T. L., Bazhenova, L. A., Romero, J., Fanta, P. T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0795 · Cited by 184
Self-citationMolecular Analysis for Therapy Choice: NCI MATCH
Conley, B. A., & Doroshow, J. H. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.05.002 · Cited by 179
Schmidt, K. T., Chau, C. H., Price, D. K., & Figg, W. D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.765 · Cited by 129
Defining actionable mutations for oncology therapeutic development
Carr, T. H., McEwen, R. K., Dougherty, B. A., Johnson, J. H., Dry, J. R., Lai, Z., Ghazoui, Z. F., Laing, N. M., Hodgson, D., Cruzalegui, F. H., et al. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.35 · Cited by 128
CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
Mao, Y., Chen, H., Liang, H., Meric‐Bernstam, F., Mills, G. B., & Chen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077945 · Cited by 123
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers
Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L. H., Cheng, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10606 · Cited by 111
Frousios, K., Iliopoulos, C. S., Schlitt, T., & Simpson, M. A. (2013) · Genomics · doi:10.1016/j.ygeno.2013.06.005 · Cited by 100
A Combined Functional Annotation Score for Non-Synonymous Variants
Lopes, M. C., Joyce, C., Ritchie, G. R. S., John, S., Cunningham, F. M., Asimit, J. L., & Zeggini, E. (2012) · Human Heredity · doi:10.1159/000334984 · Cited by 99
Sukhai, M. A., Craddock, K. J., Thomas, M., Hansen, A. R., Zhang, T., Siu, L. L., Bedard, P. L., Stockley, T. L., & Kamel‐Reid, S. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.47 · Cited by 98
Yeh, P. G., Chen, H., Andrews, J., Naser, R., Pao, W. J., & Horn, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1894 · Cited by 98
Precision medicine needs randomized clinical trials
Saad, E. D., Paolettí, X., Burzykowski, T., & Buyse, M. E. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.8 · Cited by 98
Molecular landscape of pancreatic cancer: implications for current clinical trials
Heestand, G. M., & Kurzrock, R. (2015) · Oncotarget · doi:10.18632/oncotarget.2972 · Cited by 97
Self-citationGenomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm
Turski, M. L., Vidwans, S. J., Jankú, F., Garrido‐Laguna, I., Munoz, J., Schwab, R. B., Subbiah, V., Rodon, J. A., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0643 · Cited by 90
Self-citationPrecision medicine: lessons learned from the SHIVA trial
Tsimberidou, A. M., & Kurzrock, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00397-6 · Cited by 88
Self-citationNext-Generation Sequencing to Guide Clinical Trials
Siu, L. L., Conley, B. A., Boerner, S. A., & LoRusso, P. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3215 · Cited by 77
Parker, B. A., Schwaederle, M. C., Scur, M. D., Boles, S. G., Helsten, T. L., Subramanian, R., Schwab, R. B., & Kurzrock, R. (2015) · Journal of Oncology Practice · doi:10.1200/jop.2015.004127 · Cited by 72
Self-citationJohnson, A. M., Zeng, J., Bailey, A. M., Holla, V. R., Litzenburger, B. C., Lara-Guerra, H., Mills, G. B., Mendelsohn, J. M., Shaw, K. R. M., & Meric‐Bernstam, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.013 · Cited by 71
Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
Kummar, S., Williams, P. M., Lih, C., Polley, E. C., Chen, A. P., Rubinstein, L., Zhao, Y., Simon, R. M., Conley, B. A., & Doroshow, J. H. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv003 · Cited by 59
Javle, M. M., Hainsworth, J. D., Swanton, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.402 · Cited by 59
It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
Westin, J. R., & Kurzrock, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0473 · Cited by 56
Self-citationNext-Generation Sequencing in Oncology in the Era of Precision Medicine
Blumenthal, G. M., Mansfield, E. A., & Pazdur, R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4503 · Cited by 56
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.
Bailey, A. M., Mao, Y., Zeng, J., et al. (2014) · PubMed · Cited by 50
Precision medicine in oncology: New practice models and roles for oncology pharmacists
Walko, C. M., Kiel, P. J., & Kolesar, J. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160211 · Cited by 44
Hurwitz, H. I., Raghav, K. P. S., Burris, H. A., Kurzrock, R., Sweeney, C. J., Meric‐Bernstam, F., Vanderwalde, A. M., Spigel, D. R., Bose, R., Fakih, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.676 · Cited by 38
Self-citationA framework for genomic biomarker actionability and its use in clinical decision making
Vidwans, S. J., Turski, M. L., Jankú, F., Garrido‐Laguna, I., Munoz, J., Schwab, R. B., Subbiah, V., Rodon, J. A., & Kurzrock, R. (2014) · Oncoscience · doi:10.18632/oncoscience.90 · Cited by 32
Self-citationThe Signature Program: Bringing the Protocol to the Patient
Kang, B., Slosberg, E. D., Snodgrass, S. M., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.126 · Cited by 26
Precision medicine in oncology drug development: a pharma perspective
Hollingsworth, S. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.005 · Cited by 26
MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer
Gauthier, N. P., Reznik, E., Gao, J., Sümer, S. O., Schultz, N. D., Sander, C., & Miller, M. L. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1132 · Cited by 24
Bryce, A. H., Kurzrock, R., Meric‐Bernstam, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.348 · Cited by 19
Self-citationCurating the Way to Better Determinants of Genetic Risk
Phimister, E. G. (2015) · New England Journal of Medicine · doi:10.1056/nejme1506276 · Cited by 14
Is Personalized Medicine Here?
Carneiro, B. A., Costa, R. L. B., Taxter, T., Chandra, S., Chae, Y. K., Cristofanilli, M., & Giles, F. J. (2016) · PubMed · Cited by 12
Self-citationSuccessful implementation of a novel trial model: The Signature program.
Peguero, J. A., Knost, J. A., Bauer, T. M., Taylor, M. H., Braiteh, F. S., Eder, J. P., Safran, H. P., O’Neil, B. H., Alva, A. S., Nadauld, L. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.106 · Cited by 11
Peguero, J. A., O’Neil, B. H., Sohal, D. P. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2528 · Cited by 8
Hainsworth, J. D., Meric‐Bernstam, F., Swanton, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.18_suppl.lba11511 · Cited by 7
Burris, H. A., Hurwitz, H. I., Perez, E. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps11111 · Cited by 7
Genomically guided cancer treatments: from "promising" to "clinically useful"
Conley, B. A. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv168 · Cited by 5
Rowe, K. G. (2017) · AMIA · Cited by 1
Cited by
Sorted by citations
A brief history of human disease genetics
Claussnitzer, M., Cho, J. H., Collins, R., Cox, N. J., Dermitzakis, E. T., Hurles, M. E., Kathiresan, S., Kenny, E. E., Lindgren, C. M., MacArthur, D. G., et al. (2020) · Nature · doi:10.1038/s41586-019-1879-7 · Cited by 697
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
Metadata
- Authors
- Chae, Y. K., Pan, A. P., Davis, A. A., Patel, S. P., Carneiro, B. A., Kurzrock, R., & Giles, F. J.
- Affiliations
- Northwestern University (US)
- University of California San Diego (US)
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2017-12-01
- Volume
- 16
- Issue
- 12
- Pages
- 2645-2655
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2773480817
- Cited by
- 70
- References
- 65
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 10 · 2019: 9 · 2018: 3
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- precision oncology, targeted therapy, molecular tumor board, decision support system, variant alleles, bioinformatics software, clinical management, patient-centered care
- MeSH terms
- Psychosocial Support Systems, Humans, Medical Oncology, Precision Medicine, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
